BTG Live Discussion

d gaser 30 Apr 2018

Optalis Cardiovascular trial Results look very good BTG OPTALYSE P/E RESULTS are presented to the Society for Cardiovascular Angiography BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.Full info go to www.4-traders.com/BTG-9583552/news/BTG-OPTALYSE-PE-Results-Presented-at-Society-for-Cardiovascular-Angiography-and-Interventions-26450039/BE HAPPYDAVE

d gaser 25 Apr 2018

To days news regarding OCL 500 prostrate beads Today Nice have gibven permission for beads to be used in prostrate Embolotherapy, this procedure involves the injection of embolic agents through a catheter into blood vessels that supply certain tissues in order to cut their blood flow supply and, consequently, diminish or destroy them. It appears that BTG have some I'm put into this, see notice below especially the last paragraph BE HAPPYDAVE Such a procedure has an attractive therapeutic benefit for patients with benign prostate hypertrophy (BPH), where prostate enlargement often leads to bladder outflow obstruction and a series of lower urinary tract symptoms (LUTS) that can decrease patients’ overall quality of life. OCL500 is an embolization agent representing a new approach to embolotherapy. It relies on microspheres that create a firm platelet-rich and site-specific clot that cuts the blood flow to the enlarged tissue. One of its main advantages is that, unlike other embolic microspheres on the market, OCL500 microspheres are biodegradable and do not stay in the patient’s body for life.IMB is developing OCL503 under a licensing agreement with the company BTG plc and has received regulatory clearance from the United States Food and Drug Administration (FDA) to use OCL 500 in the treatment of unresectable/inoperable hypervascularized tumors. The product is currently in development for a series of conditions, including uterine fibroids, and BPH. The clinical trial (NCT02509975), estimated to end in March 2017, is currently recruiting and has as its primary endpoints the safety of OCL500, as reported by adverse events occurrence, and International Prostate Symptom Score (IPSS) improvements.Mike Stewart, CEO of IMB, stated in a press release, “We are pleased to announce the treatment of the first patient with OCL 500 in this prostate artery embolization study. This is an important step toward expanding the labeling for our lead product. Our relationship with BTG, a world leader in innovative embolic products, is pivotal to the successful development and commercialization of OCL 500.”Print This PageClick here to receive BPH news vi

dave297 19 Apr 2018

Takeover potential ? Seems to be a topical discussion in the sector & I hope that if any one is interested in relieving me of my remaining BTG shares at a premium may also be interested in taking VEC at the same time ( allbeit for a higher premium)

Denis Filby 11 Apr 2018

Re: Long term growth potential I just regret I did not sell half my holding when the price ticked up a bit. I certainly intended too, like Mike Land. See our posts of six months ago. So, yes, you are right that long term holders are getting pretty cheesed off. Maybe BTG is going to sell up to a US company soon. So long as we can see a good profit who cares.

up protherics 10 Apr 2018

Re: Long term growth potential pauo I,m the same as you .. Holding roughly the same amount,that's interesting.. As it means a lot of long term holders have had enoug

pauloverdi 10 Apr 2018

Re: Long term growth potential I agree with the sentiments posted recently especially degaser!! Don't forget sheet al have taken numerous share options and used them to pay off her nusband in the divorce case !!! She has never suffered financially and I agree that she has ignored Europe !!Whatever happens her golden handcuff deal will not effect her one bit !! She'll come out laughing!!She has never ever given any concern for the shareholders !!I reduced last year by half and still hold 15000 shares but like others if the rise continues I'll be out !! Best wishes to all the long term eras and excellent posts and info.Paulo

d gaser 10 Apr 2018

Re: Long term growth potential I’ve given both of you a tick ,as my personal feeling about this company are very similar to your own ,however how, we have been here many times before over the past 6 years ,and then recovered quickly see chart ?.We also have to admit that BTG products are selling well, especially the the beads they are showing double digit growth ,even Varithiena is growing this year, now that's a positive don't you think . I like your selfs would also like to see another company, or a new C.E.O take over soon who see's the world differently .As I have said before I believe thier is growth here, but it lays in Europe ,and the rest of the world ,and the Lady doesn’t in my opinion understand that ,she is blind to the rest of the would ,for instance our turn over shows 80% of BTG goods were sold in the USA last year,and only 7% were sold in Europe ,even though it has over 400million people ,then you have the rest of the world with over 1.5trillion ,so I ask myself ,WHY is she so blind to these other markets ?I think Dave has the answer,maybe she is looking for a retirement pot, and is hopping a big company with in the USA will buy us out, if not ,then why are we giving cash to the American S.I.O ,and not UK equivalent ?,BTG say it’s because we are a leader in Interventional Oncology therapies, but that applies to both countries ,and they are proud to support this independent research fund ,in partnership with the S.I.O. well maybe they could also help the UK universities as well ,by offering them grants as well ..BE HAPPYDAVE www.4-traders.com/BTG-9583552/news/BTG-SIO-and-BTG-Announce-Recipients-of-Immuno-Oncology-Interventional-Oncology-Grant-Program-26280492/

dave297 10 Apr 2018

Re: Long term growth potential And yet since the fairly dire RNS last week our SP has recovered fairly strongly when some may have have expected a continued retread towards 500p.Perhaps a predator may be lurking or the Dame wants an exit & her best bet is to sell it ?

d gaser 09 Apr 2018

Long term growth potential Interesting article regarding BTG long term growth potential by investomania, for the full story see link BE HAPPYDAVE BTG plcThe BTG plc (LON:BTG) (BTG.L) share price has fallen by 7% today after it released an update for the year to 31 March 2018.It has delivered revenue that is in line with expectations in what was generally a successful year for the business. It experienced good growth in Interventional Medicine product sales, with mid-teens CER growth in the oncology and vascular portfolios. Together they represent more than 90% of the revenue in that business.Sales of the earlier-stage Interventional Medicine assets were flat at CER, with growth in Varithena sales being offset by lower sales of the PneumRx Coils. [link]

d gaser 07 Apr 2018

Interesting reading from Barclays Todays up date from Barclays interesting reading BE HAPPYDAVE FTSE 100:Intraday Fri 6 Apr 2018(ShareCast News) - Analysts at JP Morgan took a fresh look at British pharmaceutical company BTG on Friday, cutting their target price on the back of lower forecasts for sales of its Roxwood and Varithena products, but above all as a result of the anticipated lower contribution from PneumRX - its upcoming lung therapy - and due to foreign exchange headwinds.The company's 2018 pre-close trading update was as expected, but the outfit's caution on its PneumRx product, which management warned would not live up to expectations, saw its shares register their biggest single-day decline in a decade.JPM's analysts noted that while overall top-line performance was in line with guidance, BTG's update on PneumRx led to a £150m impairment on the asset, lowering expectations and leaving the group looking at "immaterial" sales for that product across the next two years."We await FY18 results on May 15th to get a clearer view on BTG's longer-term growth outlook, but we do see current levels as more attractive from a valuation perspective, with PneumRx now de-risked," they added."We take our PneumRx sales down to low-single-digit for the next two years, with sales remaining only mid-single-digit longer term. After also lowering PneumRx OpEx, PneumRx no longer makes a positive contribution to our NPV," James Gordon and his team at JPM noted on Friday morning.JPM also said that BTG's lower group tax rate as a result of Donald Trump's recent amendments to the US tax code, down from 25.5% to 21% for its current trading year, was likely to be "largely offset" by marking-to-market on FX due to the strength of sterling against the US dollar.

d gaser 05 Apr 2018

Could they be clearing the decks for a take over? Its Just a thought, but maybe BTG are clearing the decks for a take over? As we all know, many companies in the USA are now returning capital to the USA, and want to use it to develop or enlarge their own companies, while the U.S tax system is in their favour . here is some thing interesting www.4-traders.com/BTG-9583552/news/BTG-SIO-and-BTG-Announce-Recipients-of-Immuno-Oncology-Interventional-Oncology-Grant-Program-26280492/So Here's hoping BE HAPPY DAVE

d gaser 05 Apr 2018

Re: Ouch! Well I Must admit I didn't expect this .To me it seems this company find problems every year with some product or other ,it's been years since this company actually came out and delivered a good set of accounts ,that didn't contain some form of bad news,.I/E problems in the states getting agreements and payments settled ,or BTG being taken to court over negligence ,or another company trying to copy our Intellectual property rights , the list goes' on. So when are they going to get some one to take control of this company, and expand it into the rest of the world ,as it's obvious that there U.S only strategy is not working ?I bet the Lady still picks up millions of free shares for failure . BE HAPPYDAVE BTG05 Apr 2018 0703BTG PLCRNS Number : 8732JBTG PLC05 April 2018 BTG plc: close period update London, UK, 5 April 2018: BTG plc (LSE: BTG), the global healthcare company, provides the following update for the year ended 31 March 2018. BTG has delivered a good financial performance for the year, with revenue in line with expectations. Very good growth in Interventional Medicine product sales reflects mid-teens CER1 growth in the oncology and vascular portfolios, which together represent >90% of revenue in this business. Sales of the earlier-stage Interventional Medicine assets were broadly flat at CER, where growth in Varithena® sales was offset by lower sales of the PneumRx Coils®. In the Pharmaceuticals business, product sales have grown around mid-single digits at CER. Licensing has performed well, with single-digit revenue growth at CER. During the year we continued to make strong progress in clinical development, geographic expansion and product innovation. Enrolment was completed into the TheraSphere® STOP-HCC liver cancer trial. The first patients were treated with TheraSphere® in Latin America, Taiwan and Israel, and the first patients in Europe were treated with the novel radiopaque chemo-embolising bead, DC Bead LUMI™. Visual-ICE MRI, a new cryoablation system and needles from Galil Medical that are compatible with all Magnetic Resonance Imaging (MRI) scanners, received 510(k) and CE Mark regulatory clearances, and the first systems have been installed with customers. One-year data from the OPTALYSE PE trial reinforced the safety and efficacy of shorter, lower-dose EKOS® therapy for pulmonary embolism, showing continued improvement in right ventricular / left ventricular ratios and in quality of life. Lower sales of the PneumRx® Coils reflect that market development, including securing appropriate levels of reimbursement, is taking longer than expected. We believe there is a significant long-term opportunity for the Coils and are taking action to focus resources on key activities to build long-term value. These include initiating the ELEVATE clinical study to generate additional data to support market development, and progressing the Premarket Approval application in the US, where an Advisory Committee Panel meeting is expected during the summer with potential approval by the end of 2018. Market development including accessing reimbursement will also take time in the US. As a consequence of this, and of prioritising European patients into the ELEVATE study, we do not expect material revenues from this product over the next two years. We have therefore reassessed the fair value of this asset, and our financial results for 2017/18 will include an impairment charge of approximately £150m. In addition, our 2018/19 results will include a one-off restructuring charge of up to £10m. The introduction of new reimbursement codes for Varithena® in the US in January 2018 has led to renewed physician interest in the product. However, as previously noted, it will take time to see the impact of the codes on physician and insurer practice. We expect to have a better understanding of physician ordering and reordering patterns by the end of 2018. During the period, growth

up protherics 05 Apr 2018

Re: Ouch! This has been a basket case for the past four years.It has only survived up until now . Thanks to proteus/protherics products.the management have consistently been inept in their duties and have only left when pushed out. albeit with a tens of millions of losses which should/could have been avoided in the first place.So in summary... PATHETICHave people also noticed that the spiv brigade published this nonscence at the beginning of the new tax year ?????????????????????????????????????????

rikid 05 Apr 2018

Ouch! Back to a fiver now I expect : (

d gaser 04 Apr 2018

Re: Results The end of year results are normally published in may ,as our financial year ends 31 March.BE HAPPYDAVE